8-K: Tonix Pharmaceuticals Presents Promising Preclinical Data on Gastric Cancer Treatment at AACR 2025

Tonix Pharmaceuticals presented preclinical data at the AACR 2025 Annual Meeting, demonstrating that a combination treatment involving TFF2 and an anti-PD1 antibody showed promise in reducing immunosuppression in gastric cancer models.

Summary

• Tonix Pharmaceuticals presented data at the American Association for Cancer Research (AACR) 2025 Annual Meeting on April 28, 2025.
• The presentation highlighted preclinical data on gastric cancer models, focusing on a combination treatment of Trefoil Factor Family Member 2 (TFF2) with an anti-PD1 antibody.
• The study demonstrated that the combination therapy was associated with the activation of cancer-killing CD8+ T cells and limiting immune evasion by tumor cells in animal models.
• Tonix is developing TNX-1700, a human TFF2-human serum albumin (hTFF2-HAS), as a potential treatment for gastric and colorectal cancers.
• The data showed that TFF2-MSA selectively reduces immunosuppressive neutrophils and cancer-driven granulopoiesis.
• Treatment with TFF2-MSA, in combination with an anti-PD1 antibody, induced robust anti-tumoral CD8+ T cell responses, inhibiting tumor invasion.
• TFF2 reduction correlated with elevated PMN-MDSCs in gastric cancer patients, suggesting a potential negative correlation between TFF2 and PMN-MDSCs levels.
• Tonix is also developing TNX-102 SL for fibromyalgia, with a PDUFA goal date of August 15, 2025.

Sentiment

Score: 7

Explanation: The document presents positive preclinical data, suggesting potential for a new cancer treatment. However, it's important to remember that preclinical results don't always translate to clinical success, and the company faces regulatory and competitive risks.

Positives

• Preclinical data suggests that TFF2 in combination with anti-PD1 antibody shows promise in reducing immunosuppression in the tumor microenvironment.
• The combination therapy was associated with the activation of cancer-killing CD8+ T cells and limiting immune evasion by tumor cells.
• TNX-1700 is in preclinical development for gastric and colorectal cancers.
• TFF2-MSA selectively reduces immunosuppressive neutrophils and cancer-driven granulopoiesis.
• Tonix has a PDUFA goal date of August 15, 2025, for TNX-102 SL in fibromyalgia.

Negatives

• The data presented is preclinical, meaning the results are from animal models and may not translate to humans.
• TNX-1700 is still in preclinical development, and there is no guarantee it will be successful in clinical trials.
• The press release contains forward-looking statements that are subject to risks and uncertainties, and actual results may differ materially.

Risks

• The success of TNX-1700 is dependent on positive results from future clinical trials.
• The development and commercialization of new pharmaceutical products are subject to regulatory risks, including the need to obtain FDA approval.
• The company faces competition from other companies developing treatments for gastric and colorectal cancers.
• The company's financial performance is subject to risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.

Future Outlook

The company plans to continue developing TNX-1700 (TFF2-HAS) as the lead program in its immuno-oncology pipeline, testing potential dosing strategies and establishing potential clinical biomarkers through preclinical models.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, stated that the combination therapy of mTFF2-MSA with anti-PD1 treatment shows promise in reducing immunosuppression in the tumor microenvironment in animal models.
• Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, stated that they are excited to develop TNX-1700 (TFF2-HAS) as the lead program in their immuno-oncology pipeline, by testing potential dosing strategies, and establishing potential clinical biomarkers through preclinical models.

Industry Context

The announcement is relevant to the immuno-oncology field, where researchers are exploring novel combination therapies to enhance the effectiveness of cancer treatments. The focus on TFF2 and its role in modulating the tumor microenvironment aligns with current research trends aimed at overcoming immunosuppression and improving anti-tumor immunity.

Comparison to Industry Standards

• The approach of combining TFF2 with anti-PD1 therapy aligns with the broader industry trend of combining immunotherapies to enhance efficacy.
• Companies like Merck (Keytruda) and Bristol-Myers Squibb (Opdivo) have established anti-PD1 therapies as cornerstones in cancer treatment, and Tonix's approach seeks to improve upon these by targeting the tumor microenvironment.
• The use of animal models to demonstrate the efficacy of the combination therapy is standard practice in preclinical development, similar to studies conducted by other pharmaceutical companies like Amgen and Roche.

Stakeholder Impact

• Positive results could benefit shareholders through increased stock value.
• Successful development of TNX-1700 could provide a new treatment option for patients with gastric and colorectal cancers.
• Employees may benefit from the company's growth and success.
• The company's research collaborations could benefit academic institutions and researchers.

Next Steps

• Tonix plans to continue preclinical development of TNX-1700, including testing potential dosing strategies and establishing potential clinical biomarkers.
• The company will likely need to conduct clinical trials to evaluate the safety and efficacy of TNX-1700 in humans.
• Tonix anticipates a decision on marketing authorization for TNX-102 SL in fibromyalgia by August 15, 2025.

Key Dates

Keywords

TNX-1700, TFF2, Gastric Cancer, Colorectal Cancer, Immunosuppression, Anti-PD1 Antibody, AACR, Tonix Pharmaceuticals, Oncology, Preclinical Data